Respiratory System

Overview

This report looks at prescribing trends in primary care for the Respiratory System at SICBL and ICB level with particular focus on bronchodilators and corticosteroids. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for respiratory drugs based on the NHS England Right Care indicators.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Quarterly

Data Period

January 2021 to December 2023

Antibacterial drugs

Overview

This report looks at prescribing trends in primary care for antibacterial drugs at SICBL and ICB level with particular focus on prescribing volume of antibacterial agents such as cephalosporins, quinolones, macrolides and tetracyclines. Prescribing data is weighted with STAR-PU prescribing measures, and incorporates C. difficile rates and non-medical prescribing.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Quarterly

Data Period

January 2021 to December 2023

Prescribing Update Newsletter – March 2024

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on recent RDTC publications and the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources.

View the preview below on desktop, or click here to download a copy

Monthly formulary amendments – March 2024

Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines.  This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.

This edition covers guidance and alerts published in March 2024.

It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Updated 1st May 2024 to correct a typographical error.

Shared care protocol – lithium in adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.0

Last updated: 22nd March 2024

Formulary assessment – Levomepromazine (Levorol) 6.25mg tablets

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

This publication was updated in April 2024 to reflect the licensing of an oral solution for the treatment of refractory nausea unassociated with chemotherapy.

Monthly Horizon Scanning Report – March 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Prescribing Update Newsletter – February 2024

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on the added features and updates to the RDTC Medicines Optimisation Opportunities Dashboard, and the updated version of the Inhaler Carbon Impact Assessment Tool. It also includes information on some key medicines availability issues, the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources, and another in the series of “Meet the Team” where you can get to know the people behind the work we do.

View the preview below on desktop, or click here to download a copy

Monthly formulary amendments – February 2024

Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines.  This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.

This edition covers guidance and alerts published in February 2024.

It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Shared care protocol – sulfasalazine in adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.0

Last updated: 8th March 2024